Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG)

Affiliations

PMID: 32014370
DOI: 10.1016/j.clbc.2020.01.001

Abstract

In addition to classical clinicopathologic factors, such as hormone receptor positivity, human epidermal growth factor receptor 2 (HER2) status, and tumor size, grade, and lymph node status, a number of commercially available genomic tests may be used to help inform treatment decisions for early breast cancer patients. Although these tests improve our understanding of breast cancer and help to individualize treatment decisions, clinicians face challenges when deciding on the most appropriate test to order, and the advantages, if any, of one test over another. The Breast Cancer Therapy Expert Group (BCTEG) recently convened a roundtable meeting to discuss issues surrounding the use of genomic testing in early breast cancer, with the goal of providing practical guidance on the use of these tests by the community oncologist, for whom breast cancer may be only one of many tumor types they treat. The group recognizes that genomic testing can provide important prognostic (eg, risk for recurrence), and in some cases predictive, information (eg, benefit of chemotherapy, or extended adjuvant endocrine therapy), which can be used to help guide treatment decisions in breast cancer. The available tests differ in the types of information they provide, and in the patient populations and clinical trials that were conducted to validate them. We summarize the discussion of the BCTEG on this topic, and we also consider several patient cases and clinical scenarios in which genomic testing may, or may not, be useful to guide treatment decisions for the practicing community oncologist.

Keywords: Chemotherapy; Extended adjuvant therapy; Genomic testing; Molecular profiling; Recurrence risk.

Similar articles

Endocrine Therapy and Related Issues in Hormone Receptor-Positive Early Breast Cancer: A Roundtable Discussion by the Breast Cancer Therapy Expert Group (BCTEG)
J Abraham et al. Breast Cancer Res Treat 169 (1), 1-7. May 2018. PMID 29352368. - Review
A summary of the discussion on these topics and several 'expert opinion statements' are provided herein in an effort to convey the collective insights of the panel as it …
Gene Expression Profiling for Guiding Adjuvant Chemotherapy Decisions in Women With Early Breast Cancer: An Evidence-Based and Economic Analysis
Medical Advisory Secretariat. Ont Health Technol Assess Ser 10 (23), 1-57. 2010. PMID 23074401.
A total of 26 studies were included. Of these 26 studies, only five studies were relevant to the primary questions of this review (Key Questions #2 and #3). The following …
Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-negative, Metastatic Breast Cancer: A Roundtable Discussion by The Breast Cancer Therapy Expert Group (BCTEG)
J Abraham et al. Breast Cancer Res Treat 171 (1), 11-20. Aug 2018. PMID 29725889. - Review
Thus far, three CDK 4/6 inhibitors-palbociclib, ribociclib, and more recently, abemaciclib-have been approved for use in the setting of HR+, HER2-, mBC. The degrees to wh …
Tumour Profiling Tests to Guide Adjuvant Chemotherapy Decisions in Early Breast Cancer: A Systematic Review and Economic Analysis
S Harnan et al. Health Technol Assess 23 (30), 1-328. Jun 2019. PMID 31264581.
The review suggests that all the tests can provide prognostic information on the risk of relapse; results were more varied in LN+ patients than in LN0 patients. There is …
Recommendations From the EGAPP Working Group: Does the Use of Oncotype DX Tumor Gene Expression Profiling to Guide Treatment Decisions Improve Outcomes in Patients With Breast Cancer?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group*. Genet Med 18 (8), 770-9. Aug 2016. PMID 26681310.
Until definitive evidence for clinical utility is available, clinicians must decide on a case-by-case basis whether to offer the test to patients. Although Oncotype DX te …